Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer

NCT00684294 is registered in ClinicalTrials.gov with Mary Crowley Medical Research Center as lead sponsor.

NCT NCT00684294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00684294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer
Lead sponsor
Mary Crowley Medical Research Center
Phase
Phase 1
Overall status
Terminated
Start date
May 27, 2008
Completion date
May 28, 2019
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, advanced metastatic